Evidence map›Paper›PMID 36282363›Full record

ArticleBreast cancer research and treatment2022

Intrinsic subtypes in Ethiopian breast cancer patient.

Zelalem Desalegn, Meron Yohannes, Martin Porsch, Kathrin Stückrath, Endale Anberber, Pablo Santos, Marcus Bauer, Adamu Addissie, Yonas Bekuretsion, Mathewos Assefa and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Zelalem DesalegnDepartment of Microbiology, Immunology, and Parasitology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Meron YohannesSchool of Medical Laboratory Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Martin PorschInstitute of Computer Science, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Kathrin StückrathDepartment of Gynecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Endale AnberberDepartment of Surgery, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Pablo SantosInstitute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Marcus BauerGlobal Health Working Group, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Adamu AddissieSchool of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Yonas BekuretsionDepartment of Pathology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Mathewos AssefaDepartment of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Yasin WorkuCollege of Medicine and Health Science, Wollo University, Dessie, Wollo, Ethiopia.
Lesley TaylorCity of Hope National Medical Center, Duarte, CA, USA.
Tamrat AbebeDepartment of Microbiology, Immunology, and Parasitology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Eva Johanna KantelhardtDepartment of Gynecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. eva.kantelhardt@uk-halle.de.
Martina VetterDepartment of Gynecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.ORCID http://orcid.org/0000-0002-6642-9585
Addis Ababa University · ETMartin Luther University Halle-Wittenberg · DECity Of Hope National Medical Center · USWollo University · ET

Funding

Susan G. Komen GTDR16378013
6 · The paper itself

Abstract

purposeThe recent development of multi-gene assays for gene expression profiling has contributed significantly to the understanding of the clinically and biologically heterogeneous breast cancer (BC) disease. PAM50 is one of these assays used to stratify BC patients and individualize treatment. The present study was conducted to characterize PAM50-based intrinsic subtypes among Ethiopian BC patients. PATIENTS AND

methodsFormalin-fixed paraffin-embedded tissues were collected from 334 BC patients who attended five different Ethiopian health facilities. All samples were assessed using the PAM50 algorithm for intrinsic subtyping.

resultsThe tumor samples were classified into PAM50 intrinsic subtypes as follows: 104 samples (31.1%) were luminal A, 91 samples (27.2%) were luminal B, 62 samples (18.6%) were HER2-enriched and 77 samples (23.1%) were basal-like. The intrinsic subtypes were found to be associated with clinical and histopathological parameters such as steroid hormone receptor status, HER2 status, Ki-67 proliferation index and tumor differentiation, but not with age, tumor size or histological type. An immunohistochemistry-based classification of tumors (IHC groups) was found to correlate with intrinsic subtypes.

conclusionThe distribution of the intrinsic subtypes confirms previous immunohistochemistry-based studies from Ethiopia showing potentially endocrine-sensitive tumors in more than half of the patients. Health workers in primary or secondary level health care facilities can be trained to offer endocrine therapy to improve breast cancer care. Additionally, the findings indicate that PAM50-based classification offers a robust method for the molecular classification of tumors in the Ethiopian context.

Indexed as

Breast NeoplasmsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesEthiopiaFemaleHumansPrognosisBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesBreast cancerEthiopiaIntrinsic subtypingPAM50

Identifiers

PMID36282363
PMCPMC9633534
OpenAlexW4307203474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.